HBV Treatment
EASL 2017: International Liver Congress Starts This Week in Amsterdam
- Details
- Category: HBV Treatment
- Published on Thursday, 13 April 2017 00:00
- Written by Liz Highleyman
The European Association for the Study of the Liver (EASL) International Liver Congress (ILC 2016) will take place April 19-23 at the RAI Centre in Amsterdam. The congress is one of the major annual scientific meetings covering hepatitis B and C and its complications, as well as other liver diseases. HIVandHepatitis.com and our partners at aidsmap.com will be providing on-site coverage of meeting highlights.
AASLD 2016: Lonafarnib Lowers Hepatitis Delta Levels with Acceptable Side Effects
- Details
- Category: Experimental HBV Drugs
- Published on Monday, 23 January 2017 00:00
- Written by Liz Highleyman
The hepatitis delta virus (HDV) assembly inhibitor lonafarnib reduces HDV viral load and can be safely boosted with ritonavir to allow for higher and more effective doses with acceptable gastrointestinal side effects, according to study results presented at the recent AASLD Liver Meeting in Boston.
AASLD 2016: GS-4774 Therapeutic Vaccine Shows Little Efficacy in People with Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Wednesday, 30 November 2016 00:00
- Written by Liz Highleyman
An experimental immune-based therapy for chronic hepatitis B combined with tenofovir was safe and well-tolerated, but did not lead to greater reductions in hepatitis B surface antigen (HBsAg) than the antiviral alone, according to a study reported at the AASLD Liver Meeting this month in Boston.
7. Tenofovir Alafenamide Approved for Hepatitis B
- Details
- Category: HBV Treatment
- Published on Thursday, 22 December 2016 00:00
- Written by HIVandHepatitis.com
In November the U.S. Food and Drug Administration (FDA) approved tenofovir alafenamide (TAF) for the treatment of hepatitis B, offering a new option that is easier on the bones and kidneys than the older version of tenofovir.
AASLD 2016: Nucleic Acid Polymers Reduce HBsAg Levels and Improve Control of Hepatitis B Virus
- Details
- Category: Experimental HBV Drugs
- Published on Tuesday, 22 November 2016 00:00
- Written by Liz Highleyman
The nucleic acid polymers REP 2139 and REP 2165 led to hepatitis B surface antigen (HBsAg) reduction or clearance when combined with tenofovir and pegylated interferon, according to early results from a small study presented as a late-breaker at the AASLD Liver Meeting this month in Boston. This combination may potentially enable functional control of hepatitis B if confirmed in larger studies.
Web Design and Development by